Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical studyFunding expected to extend cash runway into the second half of ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

In this article, we are going to take a look at where Aligos Therapeutics, Inc. (NASDAQ:ALGS) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect ...

Check the time stamp on this data. Updated AI-Generated Signals for Aligos Therapeutics Inc. (ALGS) available here: ALGS.

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) saw a large increase in short interest in the month of December.As of December 31st, there was short interest totalling 597,300 shares ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aligos Therapeutics (ALGS) has entered into a securities purchase agreement for a private placement that is expected to result in gross ...

SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced today ...